Detalhe da pesquisa
1.
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
N Engl J Med
; 2024 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38828951
2.
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
Lancet Haematol
; 10(10): e801-e812, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37793771
3.
Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN).
Clin Pharmacokinet
; 60(7): 887-896, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33598874
4.
Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
Lancet Respir Med
; 9(1): 69-84, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32918892